Benefit of DAA Therapy in HCV Monoinfected and HIV-HCV Coinfected Patients With Mixed Cryoglobulinemia

Civil Hospices of Lyon

Status: Completed

Conditions: Mixed Cryoglobulinemia; Hepatitis C, Chronic

Treatments: Drug: DAA treatment

Study type: Observational

Funder types: Other

Identifiers

NCT03342261

CRC_GHN_2017_002

Details and patient eligibility

About

Mixed cryoglobulinemia (MC) is common in patients with chronic hepatitis C virus (HCV) infection. Direct-acting antiviral (DAA) regimens are today very effective with sustained virological response rates (SVR12) above 90%. The objective of this study was to investigate the impact of DAA therapy on cryoglobulin clearance in patients with HCV-associated MC.

Full description

We focused on HCV patients with or without HIV with MC who had at least one cryoglobulin level assessment before and after DAA therapy and investigated the impact of DAA therapy on cryoglobulin clearance.

Enrollment: 47 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• hepatitis C virus (HCV) infected patients
• symptomatic or asymptomatic mixed cryoglobulinemia
• coinfected or not with HIV
• treated by direct-acting antiviral (DAA) treatment
• at least one cryoglobulin measurement before and after DAA

Exclusion criteria

Trial design

47 participants in 1 patient group

HCV patients with mixed cryoglobulinemia

Description:

HCV patients with or without HIV presenting a mixed cryoglobulinemia and treated with direct-acting antiviral agents

Treatment:

Drug: DAA treatment